Ara-C release from poly(acrylamide-co-monomethyl itaconate) hydrogels: In vitro and in vivo studies

Polymer Gels and Networks

Volumn 6, Issue 1, 1998, Pages 57-69

  Blanco, M D ^a   Gomez C ^a   Garcia O ^a   Teijon J M ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED DRUG DELIVERY; COPOLYMERS; DIFFUSION; DRUG PRODUCTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROGELS; PHARMACOKINETICS; POLYESTERS;

POLYACRYLAMIDES; POLYMER GELS;

ACRYLICS;

EID: 0031994242     PISSN: 09667822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-7822(98)00002-1     Document Type: Article

References (35)

1. Brondsted H, Kopecek J. Hydrogels for site specific oral drug delivery: synthesis and characterization. Biomaterials (1992);12:584-92.
2. Kost J, Langer R. Equilibrium swollen hydrogels in controlled release applications. In: Peppas NA, editors Hydrogels in medicine and pharmacy, vol. III. Boca Raton, FL: CRC Press, 1987:95-108.
3. Holland SJ, Tighe BJ, Gould PL. Polymers for biodegradable medical devices. I. The potential of polyesters as controlled macromolecular release systems. J Control Rel 1986;4:155-80.
4. Langer RS, Peppas NA. Present and future applications of biomaterials in controlled drug delivery systems. Biomaterials 1981;2:201-4.
5. Lohmann D. Controlled release-recent progress in polymeric drug delivery systems. Macromol Symp 1995;100:25-30.
6. Florence AT. Drug delivery: advances and commercial opportunities. Connect Pharma Reports 1995:29-57.
7. Calabresi P, Parks RE. Quimioterapia de las enfermedades neoplásicas. In: Goodman L, Gilman A, editors. Bases Farmacologicas de la Terapeútica. Madrid: Editorial Médica Panamericana, 1986:1179-240.
8. Liliemark JO, Paul CY, Gahrton CG, Peterson CO. Pharmacokinetics of 1-β-D-arabinofuranosylcytosine-5′-triphosphate in leukemic cells after intravenous and subcutaneous administration of 1-D-arabinofuranosylcytosine. Cancer Res 1985;45:2373-75.
9. Pallavicini MG. Cytosine arabinoside: Molecular, pharmacokinetic and cytokinetic considerations. Pharmacol Ther 1984;25:207-38.
10. Capizzi R, Courtland White J, Powell BL, Perrino F. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine. Seminars in Hematology, 1991;28(3):54-69.
11. Thomas X, Archimbaud E. Bases de l'administration intraveineuse de cytosine arabinoside dans le traitement des leucémies aigues myéloides de l'adulte. Bull Cancer 1995;82:911-22.
12. Ho DHW, Frei E. Clinical pharmacology of 1-β-D-arabinofuranosil-cytosine. Clin Pharmacol Ther 1971;12:944.
13. Nand S, Messmore HL, Patel R et al. Neurotoxicity associated with systemic high-dose cytosine arabinoside. J Clin Oncol 1986;4:571-5.
14. Bruck SD. Aspects of three types of hydrogels for biomedical applications. J Biomed Mater Res 1973;7:387-404.
15. Queen D, Evans JH, Gaylor JDS, Courtney JM, Reid WH. An in vitro assessment of wound dressing conformability. Biomaterials, 1987;8:372-6.
16. Katime I, Madoz A, Velada JL. Síntesis, caracterización de algunos derivados del ácido itacónico. Rev Iberoam Polim 1993;2:73-89.
17. Blanco MD, García O, Trigo RM, Teijón JM, Katime I. 5-Fluorouracil release from copolymeric hydrogels of itaconic acid monoester. I. Acrylamide-co-monomethyl itaconate. Biomaterials, 1996;17:1061-67.
18. Song SZ, Cardinal JR, Kim SH, Kim SW. Progestin permeation through polymer membranes. V: Progesterone release from monolithic hydrogel devices. J Pharm Sci 1981;70:216-9.
19. Duerloo MJM, Bohlken S, Kop W. Intratumoral administration of cisplatin in slow-release devices. I. Tumor response and toxicity. Cancer Chemother Pharmacol 1990;27:137-40.
20. Quock JR, Sakai RI. Stability of cytarabine in a parenteral nutrient solution. Am J Hosp Pharm 1985;42:592-4.
21. Teijón JM, Trigo RM, García O, Blanco MD. Cytarabine trapping in poly(2-hydroxyethyl methacrylate) hydrogels drug delivery studies. Biomaterials 1997;18:383-8.
22. Breithaupt H, Schick J. Determination of cytarabine and uracilarabinoside in human plasma and cerebrospinal fluid by high performance liquid chromatography. J Chromatogr 1981;225:99-106.
23. Trigo RM, Blanco MD, Huerta P, Olmo R, Teijón JM. L-Ascorbic acid release from poly(2-hydroxyethylmethacrylate) hydrogels. Polym Bull 1993;31:577-84.
24. Yean L, Bunel C, Vairon JP. Reversible inmobilization of drugs on a hydrogel matrix. 2. Diffusion of free chloroamphenicol from poly(2-hydroxyethylmethacrylate) hydrogels. Makromol Chem 1990;191:1119-29.
25. Wang PY, Saniji NA. Temporary skin substitute from nonantigenic dextran hydrogel. In: Gebelin C G, Koblitz, editors. Biomedical and dental applications of polymers. New York: Plenum Press, 1981:29-37.
26. García O, Trigo RM, Blanco MD, Teijón JM. Influence of degree of crosslinking on 5-fluorouracil release from poly(2-hydroxyethyl metacrylate) hydrogels. Biomaterials 1994;15:689-94.
27. Allen TM, Mehra T, Hansen C, Cheel Chin Y. Stealth Liposomes: an improved sustained release system for 1-β-D-arabinofuranosylcytosine. Cancer Res 1992;52:2431-39.
28. Riva CM, Rustum YM, Preisler HD. Pharmacokinetics and cellular determinants of response to 1-β-Arabinofuranosylcytosine (Ara-C). Seminars in Oncology, 1985;12(2), Suppl 3:1-8.
29. 4-(4-carboxy-butyryl)-ara-C and ethylenediamine-introduced dextran. Drug release profiles and further in vivo study of its antitumor effects. Drug Desing Deliv 1991;7:139.
30. Agur Z, Arnon R, Schechter B, Effect of the dosing interval on mylotoxicity and survival in mice treated by cytarabine. Eur J Cancer 1992;28A(6/7):1085-90.
31. White JC, Rathmell JP, Capizzi RL. Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells. J Clin Invest 1987;79:380-87.
32. Capizzi RL, Yang JL, Cheng E et al. Alteration of the pharmacokinetics of high dose ara-C by its metabolite, high ara-U in patients with acute leukemia. J Clin Oncol 1983;1:763-71.
33. Kufe DW. Cytarabine (ara-C) in the treatment of preleukemia. In: Current Hospital Topics. The Upjohn Company, 1985:1-11.
34. Boos J, Bomelburg T, Gerding H, Jurgens H. Is there a relationship between cytarabine pharmacokinetics and keratitis? - A case report. Int. J. Clin Pharmacol Ther Toxicol 1993;31(12):593-6.
35. Kim S, Kim DJ, Geyer MA, Howell SB. Multivesicular liposomes containing 1-β-D-arabinofuranosylcytosine for slow-release intratecal therapy. Cancer Res 1987;47:3935-7.